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Background: Based on recent clinical trial evidence, updated treatment guidelines in the UK 
recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of 
cardiovascular disease. However, with this high statin dose, there are concerns about a 
potential increase in the incidence of statin-ƌĞůĂƚĞĚƐŝĚĞĞĨĨĞĐƚƐ ?ǁŚŝĐŚŵŝŐŚƚĂĨĨĞĐƚƉĂƚŝĞŶƚƐ ?
adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of 
statin intensity on adherence and persistence to therapy. 
Objectives: To evaluate adherence, discontinuation, and persistence to high-intensity statin 
in comparison to moderate and low-intensity in Scotland. 
Methods: Retrospective cohort study using linked health records. The study population 
included patients  ?ш ? ?ǇĞĂƌƐ ?initiated on statins between January 2010 and December 
2015. Statin treatment was stratified into high, moderate, and low-intensity based on the 
current National Institute for Health and Care Excellence classifications. Treatment 
discontinuation and persistence were evaluated using the refill-gap and anniversary 
methods, respectively; adherence was assessed by calculating the proportion of days 
covered (PDC). 
Results: A total of 73,716 patients (mean age 61.4 years [SD 12.6]) initiated statins during 
the study period: high-intensity n=7,163 (9.7%), moderate-intensity n=65,125 (88.3%), and 
low-intensity n=1,428 (1.9%). High-intensity therapy was more common among males 
(10.7%) than females (8.6%), and most common (17.1%) in the youngest age group (18  ? 24 
years). The majority of patients initiating high-intensity treatment received either 
atorvastatin 20mg (43.1%) or 40mg (32.3%), while 22.8% received atorvastatin 80mg. Crude 
discontinuation rates (50.9% high-intensity versus 75.5% low-intensity) and 1-year 
persistence  (74.7% high-intensity versus 53.1% low-intensity) differed significantly between 
intensity levels; crude adherence  ?Wш ? ?й ?was highest among high-intensity patients 
with 63.7%, compared to 51.6% and 40.5% in moderate and low-intensity, respectively. 
Conclusion: Increasing the intensity of statin therapy does not seem to negatively impact 
adherence and persistence to treatment, although findings could be due to confounders 
(e.g. primary versus secondary prevention) and/or the low proportion of patients using the 
recommended high dose statin. Further analysis is ongoing to adjust for confounders, and to 
evaluate clinical outcomes associated with high-intensity statin therapy. 
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